La catena delle opzioni mostra i dati chiave delle opzioni azionarie di SOS a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per SOS..

SOS (NYSE:SOS) Azioni, Catena delle Opzioni

SOS Ltd is a multifaceted company that leverages the power of big data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other service. The company has has three reporting segments: Commodity trading, Cryptocurrency mining and Others. Key revenue is generated from Commodity trading.

SOS Limited American Depositary Shares, one hundred and fifty (150) Class A Ordinary Shares

SOS Ltd

OpenDAO

SosTravel.com SpA

Deoleo SA

STORAGE COMPUTER CORP by Storage Computer Corp.

Storage Computer Corp

SONAE SGPS SA MAIA REG SH by Sonae SGPS SA

Sonae SGPS SA

SOUTHERN STATES SIGN CO by Southern States Sign Co.

Barclays analyst Saket Kalia maintains Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) with a Equal-Weight and raises the price target from $34 to $44.

News

Price Target

Analyst Ratings

NCNO

Barclays Maintains Equal-Weight on Ncino, Raises Price Target to $44

On Monday, Cassava Sciences Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) stock plunged after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42160859/cassava-sciences-topline-phase-3-data-did-not-meet-co-primary-endpoints" rel="noreferrer noopener">Alzheimer&#8217;s disease</a>.
The trial did not meet the pre-specified co-primary, secondary, and exploratory biomarker endpoints.
In July, CEO Rick Barry wrote a letter to shareholders and employees, saying that the company is in the final stages of testing simufilam and has significant&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41065699/sec-charges-cassava-sciences-over-manipulated-alzheimers-trial-data-company-and-former-execs-agre" rel="noreferrer noopener">financial and emotional stakes</a>.
The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 52, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing simufilam to placebo.
Simufilam continued to demonstrate an overall favorable safety profile.
&#8220;The results are disappointing&#8230;We took careful measures to enroll patients with mild-to-moderate AD. Despite that, the loss of cognition in the placebo group was less pronounced than was previously reported in other placebo-controlled studies in AD&#8230;&#8221; said&nbsp;Rick Barry, President and Chief Executive Officer.
The company said the failed trial results have impacted its second Phase 3 trial,&nbsp;ReFocus-ALZ, and decided to discontinue ReFocus-ALZ. The company will also be discontinuing the Open Label Extension study.
The complete 52-week dataset will be available from the study along with a large portion of 76-week data.
Cassava will continue to review the data and evaluate the next steps. We plan to share the detailed results at a future medical meeting.
Cassava has been in the headlines for fabricating data from <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41231890/whats-going-on-with-alzheimers-focused-cassava-sciences-on-tuesday" rel="noreferrer noopener">simufilam drug trials</a>.
In September, Cassava Sciences&nbsp;agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company&#8217;s controversial&nbsp;Alzheimer&#8217;s drug, simufilam.
The SEC also&nbsp;charged&nbsp;Hoau-Yan Wang, a consultant and co-developer of the drug, with manipulating trial results.
The SEC&#8217;s investigation found that in&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/21/08/22653801/cassava-sciences-shares-sink-with-alzheimers-drug-mired-in-controversy" rel="noreferrer noopener">September 2020</a>, Cassava disclosed manipulated data from the trial, which falsely suggested dramatic improvements in Alzheimer&#8217;s biomarkers like total tau and phosphorylated tau.
Price Action: SAVA stock is down 84.2% at $4.19 during the premarket session at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42163927/fda-approves-bridgebio-pharmas-drug-for-rare-heart-disease-poised-to-challenge-pfizer-in-lucrative-yet-competitive-market" target="_blank" rel="noreferrer noopener">FDA Approves BridgeBio Pharma&#8217;s Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market</a></li>
</ul>

Biotech

Equities

Health Care

Movers

Trading Ideas

General

SAVA

Cassava Sciences' Controversial Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Halts Late-Stage Studies

Barclays analyst Alexia Dogani maintains ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) with a Underweight and raises the price target from $13.9 to $16.5.

Barclays Maintains Underweight on ZIM Integrated Shipping, Raises Price Target to $16.5

Semler Scientific Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares are trading higher Monday. The company launched an offering and provided an update on its Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/pressreleases/24/11/n42160050/semler-scientific-announces-updated-btc-and-atm-activity">holdings</a>.
What Happened: Semler Scientific announced that it acquired 297 Bitcoin for $29.1 million in cash between Nov. 18 and Nov. 22. The company made the purchases at an average price of $97,995 per Bitcoin. 
As of Friday, Semler held a total of 1,570 Bitcoin, acquired for an aggregate of $117.8 million. 
Semler Scientific entered into a Controlled Equity Offering&nbsp;Sales Agreement with Cantor Fitzgerald in August, under which Semler may offer and sell its common stock in an at-the-market offering from time to time.
The company filed a prospectus supplement on Monday to offer an additional $50 million of shares under its existing offering with Cantor, bringing the total offering amount up to $100 million. 
Several crypto-related stocks have rallied in recent weeks as Bitcoin prices have climbed to new all-time highs just below the $100,000 level. Bitcoin was up 0.24% over a 24-hour period, trading at $97,700 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42155055/crypto-analyst-bitcoin-poised-to-skyrocket-to-180k-and-eventually-top-1m#google_vignette">Crypto Analyst: Bitcoin Poised To Skyrocket To $180K and &#8216;Eventually&#8217; Top $1M</a>
SMLR Price Action: Semler Scientific shares were up 5.11% at $66.90 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Offerings

$BTC

SMLR

What's Going On With Semler Scientific Stock Monday?

JP Morgan analyst Michael Rehaut maintains AZEK Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) with a Overweight and raises the price target from $48 to $58.

AZEK

JP Morgan Maintains Overweight on AZEK Co, Raises Price Target to $58

Morgan Stanley analyst Erik Woodring reiterates Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Overweight and maintains $273 price target.

Reiteration

AAPL

Morgan Stanley Reiterates Overweight on Apple, Maintains $273 Price Target

JP Morgan analyst Eric Joseph maintains TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) with a Overweight and raises the price target from $30 to $43.

TGTX

JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $43

Morgan Stanley analyst Devin McDermott maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Overweight and raises the price target from $45 to $56.

Morgan Stanley Maintains Overweight on EQT, Raises Price Target to $56

Decibel Cannabis Company Inc. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/DB#TSXV">DB</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/DBCCF#OTCQB">DBCCF</a>) has completed the second and final closing of its previously announced non-brokered private placement of its common shares at $0.06 per common share.
<h3 class="wp-block-heading">What Happened</h3>
The company said on Monday that, at the second closing of the offering, it issued 19,647,776 common shares for gross proceeds of roughly $1,178,867.
The second closing was in addition to the previously announced first closing in November when Decibel issued 33,503,864 common shares for gross proceeds of approximately $2,010,232.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40577591/decibels-10m-strategy-how-it-could-enhance-your-canadian-cannabis-portfolio">Decibel's $10M Strategy: How It Could Enhance Your Canadian Cannabis Portfolio</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Why It Matters</h3>
Decibel said the proceeds of the offering will be used to work on and help integrate the integration of AgMedica BioScience Inc. which he company previously<a href="https://www.benzinga.com/markets/cannabis/24/10/41600492/decibel-acquires-agmedica-announces-private-placement-and-third-quarter-guidance"> acquired</a>. The acquisition was arranged through an agreement with Callisto Capital on Oct. 28 and was made in exchange for a $6.3 million unsecured convertible debenture.
Decibel projects that AgMedica could contribute $30 million of net revenue and $4 million of EBITDA in 2025, totaling an anticipated $130 million of net revenue and $25 million of adjusted EBITDA in 2025 on a pro forma basis.
The company recently <a href="https://www.benzinga.com/24/11/42137701/canadian-cannabis-co-decibel-reports-12-yoy-drop-in-q3-revenue-but-increases-gross-margin-to-53">announced</a> its unaudited interim financial results on Thursday for the third quarter revealing CA$24.1 million ($17.2 million) in net revenue representing a 9% increase sequentially, but a 12% decrease year-over-year. However, gross margin before fair value adjustments reached 53% for the period, up from 44% in the prior year&#8217;s period, reflecting improved operational efficiency.
<h3 class="wp-block-heading">What's Next</h3>
The offering is subject to the receipt of all regulatory approvals including the final approval of the TSX Venture Exchange (TSXV).
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40369534/decibel-cannabis-reports-22-yoy-decrease-in-q2-net-revenue-plans-to-benefit-with-new-product-lau">Decibel Cannabis Reports 22% YoY Decrease In Q2 Net Revenue, Plans To Benefit With New Product Launches</a></li>
</ul>
<h3 class="wp-block-heading">DBCCF Price Action</h3>
Decibel's shares traded 1.45% higher at $0.0476 per share after the market close on Friday afternoon.

Cannabis

Financing

DBCCF

TSXV:DB

Decibel Cannabis Raises $1.18M, Secures Capital For AgMedica BioScience Integration

Morgan Stanley analyst Angel Castillo maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Overweight and raises the price target from $401 to $450.

Morgan Stanley Maintains Overweight on Deere, Raises Price Target to $450

EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) shares are trading higher after the company announced it entered into a definitive deal with funds managed by Blackstone Credit &amp; Insurance (BXCI) to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42159491/eqt-announces-3-5-billion-midstream-joint-venture-with-blackstone-credit-insurance" rel="noreferrer noopener">form a new midstream joint venture</a>.
As per the deal, BXCI will provide EQT&nbsp;$3.5 billion of cash consideration in exchange for a non-controlling equity interest in the joint venture.
This values the JV at approximately $8.8 billion, or 12x EBITDA. The deal provides EQT with a substantial equity capital solution at an accretive cost of capital.
EQT will also retain rights to growth projects linked to the contributed assets, including the planned Mountain Valley Pipeline expansion and the MVP Southgate project.
EQT intends to use the proceeds from the transaction to reduce its term loan, revolving credit facility, and redeem or tender senior notes.
Pro-forma for this deal, along with the recent sale of its remaining non-operated assets in northeast Pennsylvania, EQT expects to exit 2024 with approximately $9 billion in net debt.
EQT President and CEO&nbsp;Toby Z. Rice&nbsp;stated, &#8220;This transaction underscores the ultra-high-quality nature of EQT&#8217;s regulated midstream assets, which service one of the strongest power demand growth regions in&nbsp;the United States&nbsp;underpinned by long-term contracts with the region&#8217;s leading utilities.&#8221;
&#8221;Importantly, through this joint venture&nbsp;EQT preserves the benefits of the Equitrans acquisition by retaining the long-term value from synergy capture and growth projects. We look forward to working with Blackstone to optimize the value of these assets and together explore strategic opportunities across its leading portfolio of energy, power and digital infrastructure in the years ahead.&#8221;&nbsp;
EQT Chief Financial Officer&nbsp;Jeremy Knop&nbsp;stated, &#8220;Blackstone is a leader in providing capital solutions to large corporations and we are thrilled to partner with them in this unique transaction, crafting a tailor-made equity financing solution at a price significantly below EQT&#8217;s equity cost of capital while preserving key tax attributes. When we announced the Equitrans acquisition earlier this year, we made an unwavering commitment to debt reduction.&#8221;
&#8221;We have now delivered on that promise, with announced divestitures to date totaling&nbsp;$5.25 billion&nbsp;of projected cash proceeds, above the high-end of our&nbsp;$3 billion-$5 billion&nbsp;asset sale target, and several quarters ahead of schedule.&#8221;
The transaction is subject to customary closing adjustments, required regulatory approvals, and clearances, and is expected to close in the fourth quarter of 2024.
Investors can gain exposure to the stock via Invesco S&amp;P 500 Equal Weight Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSPG#NYSE">RSPG</a>) and First Trust Natural Gas ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCG#NYSE">FCG</a>).
Price Action: EQT shares are up 3.22% at $47.40 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/11/41997142/viking-fund-management-sells-big-oil-stocks-in-q3-cuts-tesla-position-in-half-adds-to-largest-position-broadcom" target="_blank" rel="noreferrer noopener">Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom</a></li>
</ul>

Large Cap

First Trust ISE-Revere Natural Gas Index Fund

RSPG

EQT Secures $3.5 Billion Boost: Blackstone JV To Power Midstream Expansion

Morgan Stanley analyst Lauren Schenk maintains Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) with a Overweight and raises the price target from $33 to $36.

CHWY

Morgan Stanley Maintains Overweight on Chewy, Raises Price Target to $36

JP Morgan analyst Seth Seifman maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Overweight and lowers the price target from $195 to $190.

JP Morgan Maintains Overweight on Boeing, Lowers Price Target to $190

Benchmark analyst Bill Sutherland downgrades Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) from Buy to Hold.

Downgrades

Benchmark Downgrades Select Medical Hldgs to Hold

AMC's total domestic revenue for the weekend includes revenue from admissions, along with food &amp; beverage, including merchandise
4.6 million moviegoers watched a movie at AMC Theatres in the United States and at ODEON Cinemas, AMC's international subsidiary, from Thursday to Sunday
ODEON Cinemas recorded its single-day revenue high (admissions plus food &amp; beverage) in 2024 on Saturday, November 23
AMC's domestic merchandise program continues to be popular with guests as WICKED merchandise virtually sold out by Sunday
AMC will participate in the announced WICKED Singalong showtimes, coming to theatres later in December

AMC Theatres Achieves Record Domestic Revenue Pre-Thanksgiving Weekend With 4.6M Moviegoers, Driven by WICKED and GLADIATOR II, ODEON's Single-Day High, Nearly Sold-Out WICKED Merchandise, and Anticipates Upcoming WICKED Singalong Showtimes; No Financial Terms Disclosed

Morgan Stanley analyst Michael Cyprys upgrades Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from Equal-Weight to Overweight and raises the price target from $24 to $55.

Upgrades

HOOD

Morgan Stanley Upgrades Robinhood Markets to Overweight, Raises Price Target to $55

MSTRRKLBNVDAACHRSAVATSLA$BTCLUNRMARAHOODData from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment " title="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment ">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment </a>
<ul>
<li>MSTR</li>
<li>RKLB</li>
<li>NVDA</li>
<li>ACHR</li>
<li>SAVA</li>
<li>TSLA</li>
<li>$BTC</li>
<li>LUNR</li>
<li>MARA</li>
<li>HOOD</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

ACHR

LUNR

MARA

MSTR

NVDA

RKLB

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 25, 2024 (Via Swaggy Stocks)

Bernstein analyst Gautam Chhugani maintains MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Outperform and raises the price target from $290 to $600.

Bernstein Maintains Outperform on MicroStrategy, Raises Price Target to $600

Onto Innovation's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) short percent of float has fallen 14.24% since its last report. The company recently reported that it has 1.09 million shares sold short, which is 2.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.56 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Onto Innovation Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732544122_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Onto Innovation has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Onto Innovation's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Onto Innovation's peer group average for short interest as a percentage of float is 7.91%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

ONTO

(ONTO) - Analyzing Onto Innovation's Short Interest

Genpact's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) short percent of float has risen 12.09% since its last report. The company recently reported that it has 5.20 million shares sold short, which is 3.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.95 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Genpact Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732544117_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Genpact has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Genpact's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Genpact's peer group average for short interest as a percentage of float is 6.28%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Genpact?

SOS (SOS) has released an update. SOS Limited has successfully concluded a private placement deal, raising approximately $16.99 million by selling ...

SOS Limited Secures $17M in Private Placement

SOS (SOS) has released an update. SOS Limited has announced its annual general meeting for shareholders scheduled for August 15, 2024, where key ag...

SOS Limited Gears Up for Crucial 2024 Shareholders Meeting

SOS (SOS) has released an update. SOS Limited successfully held its 2024 annual general meeting with shareholders voting to re-elect directors, rat...

SOS Limited Shareholders Support Key Resolutions

SOS Ltd announces receipt of NYSE non-compliance letter

SOS (SOS) has released an update. SOS Limited's interim financial statements reveal an increase in total assets from $483,892 thousand to $524,985 ...

SOS Limited Reports Asset Growth Amid Losses

SOS Limited announces ADS ratio change

SOS Limited (SOS) is down -11.1%, or -$1.16 to $9.34. Published first on TheFly – the ultimate source for real-time, market-moving breaking financi...

SOS Limited falls -11.1%

SOS Limited (SOS) is down -17.2%, or -$1.80 to $8.70. Published first on TheFly – the ultimate source for real-time, market-moving breaking financi...

SOS Limited falls -17.2%

SOS Limited (SOS) is down -8.5%, or -78c to $8.35. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ...

SOS Limited falls -8.5%

SOS Limited (SOS) is up 7.5%, or 56c to $8.05. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news...

SOS Limited rises 7.5%

Fintech

Press Releases

SOS Ltd. Announces Launch of Additional 1,500 mining rigs at its Super-Computing Center in Texas

SOS Ltd Provides Operating Update of its Super-Computing Centers in the U.S.

SOS Ltd. Announces Pricing of $7.85 Million Public Offering

Earnings

SOS Limited Reports 2023 Financial Results

SOS Ltd. Announces Receipt of NYSE Non-compliance Letter Regarding ADS Trading Price

SOS Limited Reports 2024 semi-annual financial results

SOS Limited Announces Planned ADS Ratio Change

Aeries Technology, Inc. - Class A Ordinary Share

Aeries Technology

ATIF Holdings

BlackSky Technology Inc. Class A Common Stock

BlackSky Technology

CRA Intl

Earlyworks Co., Ltd. - American Depositary Shares

Earlyworks Co

Sunrise New Energy Co., Ltd - Class A Ordinary Shares

Sunrise New Energy

Falcon's Beyond Global, Inc. - Class A Common Stock

Falcons Beyond Global

Franklin Covey

Forrester Res

Graphex Group Limited American Depositary Shares, each American Depositary Share representing 20 Ordinary Shares

Comments

SOS

SOS (SOS) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO